CR Bard Inc. (BCR)


NYSE - NYSE Real Time Price. Currency in USD
227.30-1.29 (-0.56%)
At close: 4:02 PM EDT
People also watch:
BDXBMSDOVCTASCINF
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open228.56
Prev Close228.59
Bid227.33 x 700
Ask227.35 x 400
Day's Range226.32 - 228.89
52wk Range172.21 - 239.43
1y Target EstN/A
Market Cap16.7B
P/E Ratio (ttm)52.86
Beta0.58
Volume453,050
Avg Vol (3m)457,073
Dividend & Yield1.04 (0.45%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Business Wire7 days ago

    LUTONIX® Global Real-World Registry 24-Month Outcomes Presented at VIVA 2016

    C. R. Bard, Inc. announced the presentation of the final 24-month results from the LUTONIX® Global Real-World Registry at the Vascular Intervention Advances 2016 Meeting.

  • C.R. Bard, Inc. (New Jersey) – Value Analysis (NYSE:BCR) : September 20, 2016
    Capital Cube9 days ago

    C.R. Bard, Inc. (New Jersey) – Value Analysis (NYSE:BCR) : September 20, 2016

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives C.R. Bard, Inc. (New Jersey) a score of 75. Our analysis is based on comparing C.R. Bard, Inc. (New Jersey) with the following peers – Boston Scientific Corporation, Teleflex Incorporated, Becton, Dickinson and Company, AngioDynamics, Inc., Merit Medical Systems, Inc., Medtronic Plc, Hologic, Inc., CryoLife, Inc. and ... Read more (Read more...)

  • CR Bard (BCR) Gets FDA's IDE Approval for Lutonix DCB
    Zacks9 days ago

    CR Bard (BCR) Gets FDA's IDE Approval for Lutonix DCB

    CR Bard Inc. (BCR) recently announced the receipt of an Investigational Device Exemption (IDE) approval from the U.S. FDA for its Lutonix 014 Drug Coated Balloon (DCB) to extend the primary endpoint of the product to a 6-month time frame.